Niklaus H Evitt studies how to improve genetic editing tools and their applications for various conditions. He works on techniques that allow scientists to make specific changes to DNA, enhancing the ability to treat genetic disorders and cancers. For instance, he has researched the CRISPR technology that can target and modify genes linked to leukemia and has developed methods for more controlled genome editing that could lead to safer therapies. Additionally, his work in hydrogen production also examines the intersection of biotechnology and renewable energy.
Key findings
Developed new base editors that can induce specific changes in DNA sequences over more than 65 base pairs, allowing for better genetic therapies.
Created split-engineered base editors that enable regulated DNA editing, enhancing safety and control during genetic modifications.
Improved CRISPR-Cas12a methods for genetic screening, identifying gene pairs that interact to negatively impact cancer cell health in leukemia models.
Discovered a new hydrogen-producing protein variant that generates almost three times more hydrogen, boosting production by 60% in another variant.
Frequently asked questions
Does Dr. Evitt study cancer treatment?
Yes, he examines genetic interactions in leukemia cells to identify new strategies for cancer treatment.
What genetic conditions does Dr. Evitt focus on?
He focuses on conditions that can be treated using advanced genetic editing techniques, including hereditary disorders.
Is Dr. Evitt's work relevant to patients with genetic disorders?
Absolutely, his research on techniques like base editing aims to improve therapies for patients with genetic conditions.
What kind of techniques does Dr. Evitt use in his research?
He uses techniques such as CRISPR and base editing to manipulate DNA and study gene interactions.
Does Dr. Evitt's research help with energy solutions?
Yes, his work on hydrogen production contributes to developing more sustainable energy technologies.
Publications in plain English
Cooperativity between Cas9 and hyperactive AID establishes broad and diversifying mutational footprints in base editors.
2024
Nucleic acids research
Berríos KN, Barka A, Gill J, Serrano JC, Bailer PF +5 more
Plain English This study examined how two components, Cas9 and a special type of enzyme called AID, work together to improve genetic editing techniques. The researchers found that these components can create a wide variety of genetic changes—specifically, they developed new base editors that can induce specific changes in DNA sequences over more than 65 base pairs. This advancement is important because it allows for more precise control and diversity in gene editing, which can lead to better treatments for genetic disorders.
Who this helps: This benefits patients with genetic conditions and the doctors who treat them.
Controllable genome editing with split-engineered base editors.
2021
Nature chemical biology
Berríos KN, Evitt NH, DeWeerd RA, Ren D, Luo M +7 more
Plain English Researchers studied a new way to control genome editing using a method called split-engineered base editors (seBEs). They found that by breaking down an enzyme into two parts, which can be reactivated with small molecules, they can precisely edit DNA while being able to regulate when the editing happens. This is a big deal because it allows for more controlled and safer genome editing compared to previous methods where the enzymes were always active.
Who this helps: This benefits scientists and patients who need more accurate and controlled gene therapies.
High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening.
2020
Nature communications
Gier RA, Budinich KA, Evitt NH, Cao Z, Freilich ES +5 more
Plain English This study focused on improving a method called CRISPR-Cas12a for testing multiple gene modifications at once in cancer cells. Researchers created a more effective version of this method, which allowed them to discover powerful interactions between certain genes that affect leukemia, specifically finding that pairs of genes (Brd9 & Jmjd6, Kat6a & Jmjd6, and Brpf1 & Jmjd6) can work together in ways that negatively impact cancer cell health. This is important because it could lead to new strategies for targeting cancer treatment.
Who this helps: This helps researchers and doctors working on cancer therapies.
High-Throughput Screening of Catalytic HProduction.
2017
Angewandte Chemie (International ed. in English)
Koo J, Schnabel T, Liong S, Evitt NH, Swartz JR
Plain English This research focused on improving the production of hydrogen using specific proteins involved in electron metabolism. The scientists created a device that can test 96 different hydrogen production reactions at once. They discovered a new version of a hydrogen-producing protein that generates almost three times more hydrogen than normal, and another protein variant that boosts hydrogen production by 60%. This finding is significant because more efficient hydrogen production can lead to better, sustainable energy solutions.
Who this helps: This helps researchers and developers involved in renewable energy technologies.
Plain English This study explored a new method for breaking down cyanobacteria using a mix of enzymes and chemicals. The researchers found that this method completely destroyed cells from various cyanobacterial strains while keeping the DNA, mRNA, and proteins intact for further analysis. This approach is easier and more reliable than existing methods, making it useful for scientists who need to study the contents of these cells.
Who this helps: This helps researchers studying cyanobacteria and their components.
Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework.
2015
The American journal of bioethics : AJOB
Evitt NH, Mascharak S, Altman RB
Plain English This research paper discusses the potential of CRISPR technology to edit genes in human embryos, which could potentially eliminate inherited diseases. The authors highlight the need for a strict set of rules to ensure the safety and ethical standards of these treatments since the National Institutes of Health has paused funding for such research. Their proposed framework aims to set up careful oversight for every step in developing these therapies to address the unique risks involved.
Who this helps: This benefits patients with hereditary disorders and researchers involved in gene therapy.